{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000041","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.817442+00:00","generated_at":"2026-06-14T06:40:08.507067+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC","bullets":["Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).","In ICI subgroup, median OS 18.5 vs 10.8 months (HR 0.63, p=0.03); in docetaxel 11.1 vs 8.7 months (HR 0.81, p=0.28).","No added systemic toxicities; most common device effect was grade 1-2 dermatitis (43%).","Company plans to submit for regulatory approval; first-line NSCLC studies underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000041","json":"https://secwatch.observer/filing/0001645113-23-000041.json","markdown":"https://secwatch.observer/filing/0001645113-23-000041.md","text":"https://secwatch.observer/filing/0001645113-23-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/0001645113-23-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/nvcr-20230606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:40:08.507067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}